US › Healthcare

Bioventus Inc (BVS)

US · Healthcare · Medical Devices

$13.42-0.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$132.1M
Revenue YoY
+6.6%
Net profit
$3.1M
Profit YoY
+218.1%
EPS
$0.15
EPS estimate
$0.07
Net margin
2.4%

EPS came in at 0.15 against a street estimate of 0.07 — a beat of 114.3%.

Key statistics

Market cap
$892.2M
P/E
32.1
Forward P/E
16.8
P/B
4.73
Book value
$2.79
EPS (TTM)
$0.41
52-week high
$13.95
52-week low
$5.81
50-day MA
$10.32
200-day MA
$8.83
Beta
0.65

Analyst view

Analysts rate Bioventus Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $14.80.

Shareholding

Insiders
11.75%
Institutions
78.57%

Largest institutional holders

FundStake
Essex Woodlands Health Ventures19.22%
Juniper Investment Co, LLC10.24%
Nantahala Capital Management, LLC9.04%
BlackRock Inc4.63%
Vanguard Capital Management, LLC2.53%
Royce & Associates, LP2.27%
Geode Capital Management, LLC1.72%
State Street Corp1.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bioventus Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.